Back to search
Nonobstructive Hypertrophic Cardiomyopathy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Nonobstructive Hypertrophic Cardiomyopathy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Nonobstructive Hypertrophic Cardiomyopathy trials you may qualify forFORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxsta…
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients…
The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (H…
This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.
The goal of this clinical trial is to learn if sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, works to treat symptomatic, nonobstructive hypertrophic cardiomy…
The EXCITE-HCM study is a randomized, controlled, blinded clinical trial designed to evaluate the effect of moderate intensity exercise training versus usual ph…
This study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).
Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study. Approximately 90…